[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-339007-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-339007-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","associations-of-concomitant-medications-with-immune-related-adverse-events-and-survival-in-advanced-cancers-treated-with-immune-checkpoint-inhibitors-a-comprehensive-pan-cancer-analysis","Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors - a comprehensive pan-cancer analysis","","Background: Concomitant medications may influence the efficacy of immune checkpoint inhibitors (ICIs), yet evidence linking such medications to the occurrence, profile, and survival impact of immune-related adverse events (irAEs) remains limited. Methods: In 851 patients with advanced cancer treated with ICIs, drug-score risk models based on antibiotics/PPIs/corticosteroids were evaluated for survival and irAEs using landmark and multivariable Cox analyses. Results: The drug score separated patients into three risk groups with distinct PFS/OS; irAEs predicted longer PFS/OS. Concomitant medications were generally linked to reduced irAEs, with PPIs showing a gastrointestinal irAE exception. Conclusions: Findings validate prognostic utility of drug score and irAEs, suggesting drug-specific immune effects.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/associations-of-concomitant-medications-with-immune-related-adverse-events-and-survival-in-advanced-cancers-treated-with-immune-checkpoint-inhibitors-a-comprehensive-pan-cancer-analysis/339007/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/associations-of-concomitant-medications-with-immune-related-adverse-events-and-survival-in-advanced-cancers-treated-with-immune-checkpoint-inhibitors-a-comprehensive-pan-cancer-analysis/339007.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the study regarding concomitant medications and irAEs?","Question",{"text":63,"@type":64},"The study evaluated associations between concomitant medications (antibiotics, PPIs, corticosteroids) and both the occurrence/profile of irAEs and survival outcomes in advanced cancers treated with ICIs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the drug score constructed and what did it measure?",{"text":68,"@type":64},"A risk model termed the “drug score” was based on concomitant medication types (antibiotics/PPIs/corticosteroids) to stratify patients and assess links with survival and irAEs.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the landmark analysis show about patients who developed irAEs?",{"text":72,"@type":64},"Patients who developed irAEs had significantly longer progression-free survival (PFS) and overall survival (OS) than those without irAEs, reducing immortal time bias.",{"name":74,"@type":61,"acceptedAnswer":75},"Were concomitant medications always associated with fewer irAEs?",{"text":76,"@type":64},"Concomitant medications were generally negatively associated with irAE occurrence, particularly endocrine irAEs; however, PPI use showed a positive association with gastrointestinal irAEs.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},339007,1790158607,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,109,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":106,"show_sort_weight":107,"slug":108},"Technology",50,"technology",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},7,"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":127,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","Open access Original research  \n Associations of concomitant  \nmedications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pancancer analysis  \nKatsuhiko Nara,1 Satoru Taguchi  ,2 Sebastiano Buti  ,3 Taketo Kawai,4 Yukari Uemura,5 Takehito Yamamoto,1 Haruki Kume,2 Tappei Takada1  \nTo cite: Nara K, Taguchi S, Buti S, et al. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis. Journal for ImmunoTherapy of Cancer 2024;12:e008806 . doi:10 . 1136/ jitc-2024-008806  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-008806](jitc-2024-008806)) .  \nAccepted 28 February 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nDr Satoru Taguchi;  \n[satorutaguchi33@gmail.com](satorutaguchi33@gmail.com)  \nABSTRACT  \nBackground While concomitant medications can affect the efficacy of immune checkpoint inhibitors (ICIs), few studies have assessed associations of concomitant medications with the occurrence and profile of immunerelated adverse events (irAEs) .  \nMethods This study assessed associations of concomitant medication (antibiotics/proton pump inhibitors (PPIs)/corticosteroids)-based risk model termed the“drug score” with survival and the occurrence and profile of irAEs in 851 patients with advanced cancer treated with ICIs (with or without other agents) . The study also assessed the survival impact of the occurrence of irAEs, using a landmark analysis to minimize immortal time bias. Multivariable Cox proportional hazard analyses were conducted for progression-free survival (PFS) and overall survival (OS) .  \nResults The drug score classified patients into three risk groups, with significantly different PFS and OS. Notably, the score’s predictive capability was better in patients treated with ICIs only than in those treated with ICIs plus other agents. The landmark analysis showed that patients who developed irAEs had significantly longer PFS and OS than those without irAEs. Generally, concomitant medications were negatively associated with the occurrence of irAEs, especially endocrine irAEs, whereas PPI use was positively associated with gastrointestinal irAEs, as an exception. Conclusions Using a large pan-cancer cohort, the prognostic ability of the drug score was validated, as well as that of the occurrence of irAEs. The negative association between concomitant medications and irAE occurrence could be an indirect measure of the detrimental effect on the immune system induced by one or more concomitant drugs.  \nINTRODUCTION  \nConcomitant medications can negatively affect the efficacy of immune checkpoint inhibitors (ICIs) for patients with cancer via changes in the gut microbiome.1–3  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Recent studies have suggested that concomitant medications such as antibiotics, proton pump inhibitors (PPIs), and corticosteroids can affect the efficacy of immune checkpoint inhibitors (ICIs). In this regard, a concomitant medication (antibiotics/PPIs/corticosteroids)-based risk model termed the “drug score” has been proposed and validated. Meanwhile, the occurrence of immunerelated adverse events (irAEs) has been reported to bea potential predictor of survival in patients treated with ICIs. However, little is known about the associations of concomitant medications with the occurrence and profile of irAEs.\u003Cbr>WHAT THIS STUDY ADDS |\n| ⇒ Using a large pan-cancer cohort of 851 patients treated with ICIs, this study validated the prognostic ability of the drug score and showed a better ab","cbCairS6NhIMD1NF","https://ap.wps.com/l/cbCairS6NhIMD1NF","pdf",1527919,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What was the purpose of the study regarding concomitant medications and irAEs?\",\"answer\":\"The study evaluated associations between concomitant medications (antibiotics, PPIs, corticosteroids) and both the occurrence/profile of irAEs and survival outcomes in advanced cancers treated with ICIs.\"},{\"question\":\"How was the drug score constructed and what did it measure?\",\"answer\":\"A risk model termed the “drug score” was based on concomitant medication types (antibiotics/PPIs/corticosteroids) to stratify patients and assess links with survival and irAEs.\"},{\"question\":\"What did the landmark analysis show about patients who developed irAEs?\",\"answer\":\"Patients who developed irAEs had significantly longer progression-free survival (PFS) and overall survival (OS) than those without irAEs, reducing immortal time bias.\"},{\"question\":\"Were concomitant medications always associated with fewer irAEs?\",\"answer\":\"Concomitant medications were generally negatively associated with irAE occurrence, particularly endocrine irAEs; however, PPI use showed a positive association with gastrointestinal irAEs.\"}]","Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors - a comprehensive pan-cancer analysis | PDF",1790027221,25,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0dadc7454c38047090f0281a5fed9b03.webp",983,1310,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4086a176b3585bf1bd236ba26f73307a.webp",982,1309,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e39f2ab10bf291af6a70cff499e56393.webp",981,1308,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cc8cceeb384ac7cf75fedb82998e262b.webp",980,1306]